Literature DB >> 29377024

Long-term registries: Answering tough questions with big data?

Robert J Fox1, Gary Cutter1.   

Abstract

Year:  2016        PMID: 29377024      PMCID: PMC5720612          DOI: 10.1212/CPJ.0000000000000226

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


× No keyword cloud information.
  5 in total

1.  Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.

Authors:  Tim Spelman; Tomas Kalincik; Vilija Jokubaitis; Annie Zhang; Fabio Pellegrini; Heinz Wiendl; Shibeshih Belachew; Robert Hyde; Freek Verheul; Alessandra Lugaresi; Eva Havrdová; Dana Horáková; Pierre Grammond; Pierre Duquette; Alexandre Prat; Gerardo Iuliano; Murat Terzi; Guillermo Izquierdo; Raymond M M Hupperts; Cavit Boz; Eugenio Pucci; Giorgio Giuliani; Patrizia Sola; Daniele L A Spitaleri; Jeannette Lechner-Scott; Roberto Bergamaschi; François Grand'Maison; Franco Granella; Ludwig Kappos; Maria Trojano; Helmut Butzkueven
Journal:  Neurol Clin Pract       Date:  2016-04

2.  Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

Authors:  Robert J Fox; David H Miller; J Theodore Phillips; Michael Hutchinson; Eva Havrdova; Mariko Kita; Minhua Yang; Kartik Raghupathi; Mark Novas; Marianne T Sweetser; Vissia Viglietta; Katherine T Dawson
Journal:  N Engl J Med       Date:  2012-09-20       Impact factor: 91.245

3.  Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.

Authors:  Ralf Gold; Ludwig Kappos; Douglas L Arnold; Amit Bar-Or; Gavin Giovannoni; Krzysztof Selmaj; Carlo Tornatore; Marianne T Sweetser; Minhua Yang; Sarah I Sheikh; Katherine T Dawson
Journal:  N Engl J Med       Date:  2012-09-20       Impact factor: 91.245

4.  Comparative efficacy of switching to natalizumab in active multiple sclerosis.

Authors:  Timothy Spelman; Tomas Kalincik; Annie Zhang; Fabio Pellegrini; Heinz Wiendl; Ludwig Kappos; Larisa Tsvetkova; Shibeshih Belachew; Robert Hyde; Freek Verheul; Francois Grand-Maison; Guillermo Izquierdo; Pierre Grammond; Pierre Duquette; Alessandra Lugaresi; Jeannette Lechner-Scott; Celia Oreja-Guevara; Raymond Hupperts; Thor Petersen; Michael Barnett; Maria Trojano; Helmut Butzkueven
Journal:  Ann Clin Transl Neurol       Date:  2015-02-27       Impact factor: 4.511

5.  Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.

Authors:  Helmut Butzkueven; Ludwig Kappos; Fabio Pellegrini; Maria Trojano; Heinz Wiendl; Radhika N Patel; Annie Zhang; Christophe Hotermans; Shibeshih Belachew
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-02-14       Impact factor: 10.154

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.